Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.47 |
| ▸ | HTR3B | O95264 | 3/20 | 0.47 |
| ▸ | HTR3A | P46098 | 3/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30837416 | 1.00 | PNMT (0.54) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL7810238 | 0.85 | PNMT (0.52) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL10381187 | 0.83 | PNMT (0.50) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL30837419 | 0.74 | TAAR1 (0.50) | TAAR1IDO1AGXT | |
| SCHEMBL3570833 | 0.74 | TAAR1 (0.50) | TAAR1IDO1 | |
| SCHEMBL776359 | 0.74 | TAAR1 (0.50) | TAAR1IDO1AGXT | |
| SCHEMBL30837414 | 0.74 | TAAR1 (0.50) | TAAR1IDO1AGXT | |
| SCHEMBL3565658 | 0.74 | TAAR1 (0.50) | TAAR1IDO1AGXT | |
| SCHEMBL24196899 | 0.74 | TAAR1 (0.46) | PNMTTAAR1CYP3A4IDO1AGXT | |
| SCHEMBL12050856 | 0.74 | TAAR1 (0.74) | PNMTTAAR1CYP3A4IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117778339-A | Sulfoxide reductase mutant and application thereof in preparation of chiral sulfoxide and sulfinyl ester | 遵义医科大学 | 2024-03-29 | — | — | CN | disclosed |
| CN-117757763-A | Sulfoxide reductase mutant and application thereof in chiral sulfoxide preparation | 遵义医科大学 | 2024-03-26 | — | — | CN | disclosed |
| US-7776582-B2 | for gas chromatography; identifying an optically enhanced chiral ionic liquid (OCIL) for enantiomeric resolution | SIGMA-ALDRICH CO. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090145197-A1 | Optically Enhanced Chiral Ionic Liquids | SIGMA-ALDRICH CO. NEWCO INC. | 2009-06-11 | — | — | US | disclosed |
| US-20060014955-A1 | Optically enhanced chiral ionic liquids | ADVANCED SEPARATION TECHNOLOGIES INC. (US) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014955-A1 | Optically enhanced chiral ionic liquids | GCG, INF2, ELOVL3 | PNMT 2412/4885TAAR1 1789/4885CYP3A4 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.